Navigation Links
Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for,Travelers' Diarrhea Stimulates Immune Response Even at Low Doses

-- Data Gathered to Assist in Design of Future Trials, Other Programs --

GAITHERSBURG, Md. and LISBON, Portugal, April 26, 2007 /PRNewswire-FirstCall/ -- Iomai Corporation today announced results from a 400-patient, Phase 2 dose-ranging trial of its patch-based vaccine for travelers' diarrhea. The trial was conducted to assess the ability of a range of vaccine doses to generate an immune response against enterotoxigenic E. coli (ETEC) bacteria -- the most common cause of travelers' diarrhea. Researchers found that even at the lowest dose tested, an Iomai patch applied to the arm generated a robust response in more than 95 percent of patients.

The results were presented today by Iomai's Vice President of Clinical Development, Sarah A. Frech, DVM, at the Vaccines for Enteric Diseases 2007 conference in Lisbon, Portugal.

"These results demonstrate the power of Iomai's technology by showing that even a small dose of vaccine, applied to the skin via a patch, is enough to stimulate a robust immune response. The data will help us determine the dose that we will use in our ETEC product," said Gregory M. Glenn, MD, Senior Vice President and Chief Scientific Officer of Iomai. "Iomai's research has shown that, in addition to showing potential benefits against ETEC, the active ingredient in the patch also works as an immune-boosting adjuvant when the patch is used in combination with injected vaccines for influenza. Thus, the results from the dose-ranging ETEC study will also help determine doses for future studies of the Iomai booster patch for seasonal and pandemic influenza."

Travelers' diarrhea sickens between 20 and 50 percent of international travelers to areas where the bacteria is endemic, but no ETEC vaccine is available in the United States. The existing strategy for avoiding travelers' diarrhea -- prophylactic antibiotics -- raises concerns about antibiotic resistance and drug side effects.< /p>

The dose-ranging trial was designed to measure levels of an antibody, IgG, that is associated with protection against enterotoxigenic E. coli. Four different doses -- 7.5 micrograms, 22.5 micrograms, 37.5 micrograms and 50 micrograms -- and a placebo patch were tested, and antibody levels were checked at 21 and 42 days. The results showed that nearly all patients in the four dosing groups responded to the vaccine, with even the lowest dose of the vaccine evoking a response in more than 95 percent of patients.

Iomai's ETEC vaccine uses "heat labile" toxin, or LT, produced by E. coli, to induce an immune response against the bacteria, and LT also functions as a potent adjuvant in the company's influenza patch programs.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has five product candidates in development: four targeting influenza and pandemic flu and one to prevent E. coli-related travelers' diarrhea. For more information on Iomai, please visit www.iomai.com .

Some matters discussed in this press release constitute "forward-looking statements" that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements about the ability of Iomai's travelers' diarrhea patch vaccine to stimulate robust immune responses , the use of these results to determine doses for future studies of Iomai's vaccine candidates for travelers' diarrhea and pandemic and seasonal influenza. Applicable risks and uncertainties include, among others, that results in the trial described in this press release may not provide the needed information necessary to conduct future trials, that Iomai may not be able to enroll sufficient numbers of patients in future clinical trials; that future clinical trials may not replicate results seen in the trials described in this press release; that Iomai may be unable to obtain the regulatory approvals necessary to conduct additional clinical trials or to market any product candidates for travelers' diarrhea, pandemic and seasonal influenza; that development costs may exceed expectations; that Iomai may fail to adequately protect its intellectual property or may be determined to infringe on the intellectual property of others; and the risks identified under the heading "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2006 and filed with the Securities and Exchange Commission. Iomai cautions investors and others not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read the Company's filings for a discussion of these and other risks and uncertainties which are filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.

These statements speak only as of the date of this document, and Iomai undertakes no obligation to update or revise the statements.

CONTACT: Russell P. Wilson, Senior Vice President, Chief Financial Officerand General Counsel of Iomai Corporation, +1-301-556-4478,; or Brian Reid of WeissComm Partners, Inc.,+1-703-402-3626, or , for Iomai Corp. investors@iomai.com breid@weisscommpartners.com

Web site: http://www.iomai.com//

Ticker Symbol: (NASDAQ-NMS:IOMI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
7. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
(Date:4/28/2016)... Florida , April 28, 2016 ... the development of innovative peptide and gene-based immunotherapeutics and vaccines ... it will be presenting at the 3rd Annual Growth ... - 5 th , 2016 at Caesars Palace in Las Vegas, ... 8.00 am on Wednesday, May 4 th by Dr. ...
(Date:4/27/2016)... 27 Avril 2016   ... de +5% sur le trimestre, soutenu par une ... Croissance de +16% des ventes aux ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), ... annonce aujourd,hui son chiffre d,affaires pour le premier ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions ... use of Microsoft Dynamics GP for one their long-term care clients. Working together ... Dynamics GP with key clinical management systems, and delivered a fully integrated accounting ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Pro3rd ... X. Utilize Pixel Film Studios’ lower thirds to introduce people, characters, and locations without ... that include boxes, lines, accents, textures and many more design components. Simply select a ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... In its ... 1Heart Caregiver Services continues its successful franchise development and expansion as it welcomes Ferdie ... extensive managerial and administrative experience in his 32 years of working in various industries. ...
(Date:4/28/2016)... ... April 29, 2016 , ... Sublime Beauty® is offering a special deal on its webstore. , ... The discount is applied to the product with lesser value. In addition, a free ... $250 or more in products. , "So many women (men, too) love our products and ...
(Date:4/28/2016)... ... April 28, 2016 , ... ProText Layouts is a set ... Pro X . With ProText Layouts, video editors can create an energetic typography ... length and scale of texts. Creating text-based videos have never been easier. , ...
Breaking Medicine News(10 mins):